Published in J Inherit Metab Dis on May 13, 2010
Lipid metabolism in myelinating glial cells: lessons from human inherited disorders and mouse models. J Lipid Res (2010) 1.31
N-Acetylaspartate reductions in brain injury: impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation. Front Neuroenergetics (2013) 0.97
Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease. PLoS One (2011) 0.94
Acetate supplementation modulates brain histone acetylation and decreases interleukin-1β expression in a rat model of neuroinflammation. J Neuroinflammation (2012) 0.90
Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease. J Inherit Metab Dis (2013) 0.88
Acetate reduces microglia inflammatory signaling in vitro. J Neurochem (2012) 0.88
Extensive aspartoacylase expression in the rat central nervous system. Glia (2011) 0.87
Acetate supplementation attenuates lipopolysaccharide-induced neuroinflammation. J Neurochem (2011) 0.87
Modulation of inflammatory cytokines and mitogen-activated protein kinases by acetate in primary astrocytes. J Neuroimmune Pharmacol (2012) 0.85
Metabolic causes of epileptic encephalopathy. Epilepsy Res Treat (2013) 0.81
Acetate supplementation induces growth arrest of NG2/PDGFRα-positive oligodendroglioma-derived tumor-initiating cells. PLoS One (2013) 0.80
Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest. J Cell Physiol (2015) 0.80
Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease. Mol Genet Metab (2010) 0.80
Acetate reduces PGE2 release and modulates phospholipase and cyclooxygenase levels in neuroglia stimulated with lipopolysaccharide. Lipids (2013) 0.79
Acetate supplementation modulates brain adenosine metabolizing enzymes and adenosine A₂A receptor levels in rats subjected to neuroinflammation. J Neuroinflammation (2014) 0.75
Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease. JCI Insight (2017) 0.75
Oral acetate supplementation attenuates N-methyl D-aspartate receptor hypofunction-induced behavioral phenotypes accompanied by restoration of acetyl-histone homeostasis. Psychopharmacology (Berl) (2016) 0.75
Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease. Front Mol Neurosci (2017) 0.75
ATP-citrate lyase links cellular metabolism to histone acetylation. Science (2009) 8.82
Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci U S A (2006) 7.00
N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol (2007) 4.63
Myelination in rat brain: method of myelin isolation. J Neurochem (1973) 4.01
Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol (2008) 3.56
HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat Neurosci (2009) 3.18
Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet (1988) 2.78
Molecular characterization of human acetyl-CoA synthetase, an enzyme regulated by sterol regulatory element-binding proteins. J Biol Chem (2000) 2.00
Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol (2000) 1.82
Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J Neurochem (2001) 1.77
Endoplasmic reticulum stress in disorders of myelinating cells. Nat Neurosci (2009) 1.76
Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther (2002) 1.60
Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A (2005) 1.60
Immunohistochemical localization of aspartoacylase in the rat central nervous system. J Comp Neurol (2004) 1.47
Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan's disease). A review. Hum Pathol (1973) 1.42
A reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1. Biochem J (2007) 1.40
Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J (1979) 1.39
Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation. Prog Neurobiol (2009) 1.37
Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med (2000) 1.27
Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. J Neurosci (2008) 1.23
Effects of nicotine on elevated plus maze and locomotor activity in male and female adolescent and adult rats. Pharmacol Biochem Behav (2004) 1.17
Acetyl transport mechanisms. Involvement of N-acetyl aspartic acid in de novo fatty acid biosynthesis in the developing rat brain. Exp Brain Res (1968) 1.13
Acetate metabolism in the nervous system. N-acetyl-L-aspartic acid and the biosynthesis of brain lipids. J Neurochem (1966) 1.10
Epigenetic mechanisms facilitating oligodendrocyte development, maturation, and aging. Glia (2009) 1.09
Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Mol Ther (2005) 1.08
Aspartoacylase is a regulated nuclear-cytoplasmic enzyme. FASEB J (2006) 1.02
Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system. J Neurochem (2000) 1.01
Nuclear-cytoplasmic localization of acetyl coenzyme a synthetase-1 in the rat brain. J Comp Neurol (2010) 0.98
Lipogenesis in the brain of suckling rats. Studies on the mechansim of mitochondrial-cytosolic carbon transfer. Biochem J (1980) 0.96
Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain. J Pharmacol Exp Ther (2005) 0.95
Identification and distribution of aspartoacylase in the postnatal rat brain. Neuroreport (2003) 0.92
Metabolic acetate therapy for the treatment of traumatic brain injury. J Neurotrauma (2010) 0.92
Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction. Drug Metab Dispos (2007) 0.92
Myelin lipid abnormalities in the aspartoacylase-deficient tremor rat. Neurochem Res (2008) 0.91
Molecular water pumps and the aetiology of Canavan disease: a case of the sorcerer's apprentice. J Inherit Metab Dis (1999) 0.90
Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation. J Mol Neurosci (2003) 0.90
Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease. Brain Res Mol Brain Res (2005) 0.89
Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease. J Neurosci Res (2009) 0.87
Triacetin: a potential parenteral nutrient. JPEN J Parenter Enteral Nutr (1991) 0.87
N-acetylaspartic aciduria in a child with a progressive cerebral atrophy. Clin Chim Acta (1986) 0.85
Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model. J Inherit Metab Dis (2009) 0.84
Total parenteral nutrition with short- and long-chain triglycerides: triacetin improves nitrogen balance in rats. J Nutr (1992) 0.81
Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse. Neurobiol Dis (2005) 0.81
NT5E mutations and arterial calcifications. N Engl J Med (2011) 8.71
The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell (2003) 8.34
Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci U S A (2006) 7.00
Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell (2010) 5.73
Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med (2008) 5.34
Natural history of alkaptonuria. N Engl J Med (2002) 5.32
Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N Engl J Med (2009) 4.96
Mechanism of human SIRT1 activation by resveratrol. J Biol Chem (2005) 4.86
Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med (2014) 4.70
N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol (2007) 4.63
Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell (2009) 4.50
Histone H3-K56 acetylation is catalyzed by histone chaperone-dependent complexes. Mol Cell (2007) 3.38
Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet (2008) 2.83
Circulating fibrocytes as biomarker of prognosis in Hermansky-Pudlak syndrome. Am J Respir Crit Care Med (2014) 2.77
SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab (2010) 2.77
Vascular pathology of medial arterial calcifications in NT5E deficiency: implications for the role of adenosine in pseudoxanthoma elasticum. Mol Genet Metab (2011) 2.65
Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol Cell (2012) 2.54
Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science (2013) 2.49
Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology (2012) 2.33
Essential role for the SANT domain in the functioning of multiple chromatin remodeling enzymes. Mol Cell (2002) 2.33
Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell (2011) 2.29
Retracted A BLOC-1 mutation screen reveals that PLDN is mutated in Hermansky-Pudlak Syndrome type 9. Am J Hum Genet (2011) 2.25
Substrate specificity and kinetic mechanism of the Sir2 family of NAD+-dependent histone/protein deacetylases. Biochemistry (2004) 2.11
Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. J Clin Invest (2007) 2.04
Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins. J Biol Chem (2013) 2.03
Long-term follow-up of well-treated nephropathic cystinosis patients. J Pediatr (2004) 2.02
The Sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol (2008) 2.00
Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood (2010) 2.00
A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab (2011) 1.98
Mechanisms and molecular probes of sirtuins. Chem Biol (2008) 1.90
Structural identification of 2'- and 3'-O-acetyl-ADP-ribose as novel metabolites derived from the Sir2 family of beta -NAD+-dependent histone/protein deacetylases. J Biol Chem (2002) 1.88
Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem (2003) 1.87
Mitochondrial autophagy promotes cellular injury in nephropathic cystinosis. J Am Soc Nephrol (2009) 1.86
Homozygosity mapping and whole-exome sequencing to detect SLC45A2 and G6PC3 mutations in a single patient with oculocutaneous albinism and neutropenia. J Invest Dermatol (2011) 1.82
Molecular functions of the histone acetyltransferase chaperone complex Rtt109-Vps75. Nat Struct Mol Biol (2008) 1.78
SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status. J Biol Chem (2012) 1.77
Use of nitisinone in patients with alkaptonuria. Metabolism (2005) 1.70
Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta (2008) 1.69
Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics. Hum Genet (2003) 1.69
Structure and biochemical functions of SIRT6. J Biol Chem (2011) 1.67
Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst (2010) 1.65
Assays for mechanistic investigations of protein/histone acetyltransferases. Methods (2005) 1.65
Casein kinase iδ mutations in familial migraine and advanced sleep phase. Sci Transl Med (2013) 1.65
Catalysis and substrate selection by histone/protein lysine acetyltransferases. Curr Opin Struct Biol (2008) 1.64
Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD+-dependent deacetylases. J Biol Chem (2002) 1.62
Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A (2005) 1.60
Binding of the CHD4 PHD2 finger to histone H3 is modulated by covalent modifications. Biochem J (2009) 1.59
Catalytic mechanism of a MYST family histone acetyltransferase. Biochemistry (2007) 1.57
Plant homeodomain (PHD) fingers of CHD4 are histone H3-binding modules with preference for unmodified H3K4 and methylated H3K9. J Biol Chem (2011) 1.55
Metabolite of SIR2 reaction modulates TRPM2 ion channel. J Biol Chem (2006) 1.55
Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases. PLoS Genet (2011) 1.54
A continuous microplate assay for sirtuins and nicotinamide-producing enzymes. Anal Biochem (2009) 1.54
Small molecule regulation of Sir2 protein deacetylases. FEBS J (2005) 1.54
Mistargeting of peroxisomal EHHADH and inherited renal Fanconi's syndrome. N Engl J Med (2014) 1.53
Molecular defects that affect platelet dense granules. Semin Thromb Hemost (2004) 1.52
Sir2 protein deacetylases: evidence for chemical intermediates and functions of a conserved histidine. Biochemistry (2006) 1.49
Craniotomy: true sham for traumatic brain injury, or a sham of a sham? J Neurotrauma (2011) 1.49
Immunohistochemical localization of aspartoacylase in the rat central nervous system. J Comp Neurol (2004) 1.47
Cellular defects in Chediak-Higashi syndrome correlate with the molecular genotype and clinical phenotype. J Invest Dermatol (2007) 1.47
IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol (2007) 1.46
Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat Genet (2004) 1.45
Hermansky-Pudlak syndrome: radiography and CT of the chest compared with pulmonary function tests and genetic studies. AJR Am J Roentgenol (2002) 1.45
Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide. Biochemistry (2007) 1.44
Heterozygous nonsense mutation SATB2 associated with cleft palate, osteoporosis, and cognitive defects. Hum Mutat (2007) 1.44
Coenzyme specificity of Sir2 protein deacetylases: implications for physiological regulation. J Biol Chem (2004) 1.43
Identification of macrodomain proteins as novel O-acetyl-ADP-ribose deacetylases. J Biol Chem (2011) 1.42
Acetyl-lysine analog peptides as mechanistic probes of protein deacetylases. J Biol Chem (2007) 1.41
Combinatorial profiling of chromatin binding modules reveals multisite discrimination. Nat Chem Biol (2010) 1.39
The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis. Mol Cell (2012) 1.39
NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules. Nat Genet (2011) 1.38
Nonsense mutations in ADTB3A cause complete deficiency of the beta3A subunit of adaptor complex-3 and severe Hermansky-Pudlak syndrome type 2. Pediatr Res (2002) 1.37
Bivalent recognition of nucleosomes by the tandem PHD fingers of the CHD4 ATPase is required for CHD4-mediated repression. Proc Natl Acad Sci U S A (2012) 1.37
Sirtuin catalysis and regulation. J Biol Chem (2012) 1.35
Integrin α3 mutations with kidney, lung, and skin disease. N Engl J Med (2012) 1.33
KAT(ching) metabolism by the tail: insight into the links between lysine acetyltransferases and metabolism. Chembiochem (2010) 1.32
Nephrocalcinosis (enamel renal syndrome) caused by autosomal recessive FAM20A mutations. Nephron Physiol (2013) 1.31
Where in the cell is SIRT3?--functional localization of an NAD+-dependent protein deacetylase. Biochem J (2008) 1.31
Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury. J Cereb Blood Flow Metab (2002) 1.29
Slc7a11 gene controls production of pheomelanin pigment and proliferation of cultured cells. Proc Natl Acad Sci U S A (2005) 1.28
Hermansky-Pudlak syndrome: vesicle formation from yeast to man. Pigment Cell Res (2002) 1.28
Analysis of DNA sequence variants detected by high-throughput sequencing. Hum Mutat (2012) 1.28
Probing the function of conserved residues in the serine/threonine phosphatase PP2Calpha. Biochemistry (2003) 1.28
Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations. Mol Genet Metab (2004) 1.26
Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference. J Pediatr (2006) 1.26
Interstitial lung disease and pulmonary fibrosis in Hermansky-Pudlak syndrome type 2, an adaptor protein-3 complex disease. Mol Med (2012) 1.26
Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation. Mol Genet Metab (2002) 1.25
DNA variations in oculocutaneous albinism: an updated mutation list and current outstanding issues in molecular diagnostics. Hum Mutat (2013) 1.25
Function and metabolism of sirtuin metabolite O-acetyl-ADP-ribose. Biochim Biophys Acta (2010) 1.25
An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia. Hum Mutat (2012) 1.25
Quantitative assays for characterization of the Sir2 family of NAD(+)-dependent deacetylases. Methods Enzymol (2004) 1.23
Cystinosis: the evolution of a treatable disease. Pediatr Nephrol (2012) 1.23